CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shire Regenerative Medicine Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shire Regenerative Medicine Inc.
36 Church Lane
Phone: (203) 682-7222p:203 682-7222 Westport, CT  06880  United States Ticker: ABHBABHB
Advanced BioHealing, Inc. filed a Registration Withdrawal Request of its Form S-1 (File No. 333-172442) on 1/30/2012. The Company is withdrawing the Registration Statement due to the acquisition of the Company.
This is a Subsidiary, click here for the Parent Company
Business Summary
Shire Regenerative Medicine Inc., formerly Advanced BioHealing, Inc., is a regenerative medicine company that develops, manufactures and commercializes cell-based therapies. The Company’s principal product, Dermagraft, has received a PMA from the United States Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers. It has sold over 200,000 units of Dermagraft that have been used to treat an estimated 50,000 patients. As of 1/7/2019, the Company is part of Shire PLC, which is owned by Takeda Pharmaceutical Company Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
4/2/20111/1/2011YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Kevin L.Rakin 54 2/1/2007 2/1/2007
Chief Financial Officer, Senior Vice President Kevin C.O'Boyle 58 12/1/2010 12/1/2010
Senior Vice President, North American Sales KeithO'Briant 46 5/1/2009 5/1/2009
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 400 (As of 4/2/2011)
Outstanding Shares: 39,821,585 (As of 4/2/2011)
Shareholders: 37
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 23, 2023